Triple Negative Breast Cancer Market Growth & Trends

The triple negative breast cancer (TNBC) market size is estimated to reach ~USD 7 billion by 2034, registering a CAGR of 4.70% from 2025 to 2034, according to a new report by DelveInsight, a pharmaceutical market research firm. Rising incidence of TNBC and expanding adoption of innovative immunotherapies and targeted treatments are the primary factors propelling market growth. Moreover, increasing advancements in antibody-drug conjugates (ADCs), checkpoint inhibitors, and PARP inhibitors by pharma companies including AstraZeneca, Daiichi Sankyo, OBI Pharma, Astellas Pharma, Pfizer, BioNTech, Galera Therapeutics, Merck, Roche, and Gilead Sciences, among others, are driving the expansion of the TNBC market.

The robust TNBC clinical pipeline demonstrating positive clinical results is a major factor driving the therapeutic market. In April 2025, Gilead Sciences reported positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, showing that the combination of TRODELVY (sacituzumab govitecan-hziy) and KEYTRUDA (pembrolizumab) significantly improved progression-free survival in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10), compared to chemotherapy and KEYTRUDA alone.

The growing TNBC prevalence globally is further fueling the TNBC market growth, as TNBC accounts for approximately 15-20% of all breast cancer cases worldwide. In 2023, there were approximately 100K incident cases of TNBC in the seven major markets (7MM). Among these 7MM, the United States has the highest incidence, with about 45K cases. Among EU4 countries and the UK, Germany reported the highest incidence with approximately 11K, followed by France.

Furthermore, innovative treatment developments and regulatory approvals are playing a crucial role in boosting market growth by expanding treatment options and improving patient outcomes. KEYTRUDA (pembrolizumab), approved in combination with chemotherapy for early-stage TNBC as well as PD-L1-positive locally recurrent or metastatic TNBC, holds Priority Review and Breakthrough Designation. Additionally, TRODELVY (sacituzumab govitecan-hziy), a TROP-2-directed ADC, is approved for metastatic TNBC patients who have received prior treatment and holds Priority Review, Breakthrough Designation, and Fast Track Designation from the FDA.

Moreover, rising investments in precision oncology and biomarker-driven therapies are providing lucrative opportunities for key TNBC companies. The current treatment landscape includes standard options like chemotherapy, immunotherapy, targeted therapy, surgery, and radiation therapy. KEYTRUDA in combination with chemotherapy, PARP inhibitors like TALZENNA (talazoparib) for BRCA-mutated TNBC, and TRODELVY for recurrent or refractory metastatic TNBC represent the current therapeutic arsenal.

Request a free sample copy or view report summary: Triple Negative Breast Cancer Market Report

Triple Negative Breast Cancer Market Report Highlights

• To keep up with current market trends, DelveInsight takes KOLs and SME's opinions working in the domain through primary research to fill the data gaps and validate our secondary research.

• The epidemiology chapter provides historical as well as forecasted epidemiology segmented by total incident cases of breast cancer, total incident cases of TNBC, gene mutation-specific cases of TNBC, stage-specific cases of TNBC, age-specific cases of TNBC, and line-wise treated incident cases of TNBC, in the 7MM.

• The report provides an edge to pharma executives by understanding the market trends through SWOT analysis and expert insights, patient journey, and treatment preferences that help in shaping and driving the 7MM Triple Negative Breast Cancer market.

• The report further contains an all-inclusive account of both the current and emerging therapies, along with the elaborate profiles of late-stage and prominent therapies, that will have an impact on the current treatment landscape.

Triple Negative Breast Cancer Market Segmentation

Triple Negative Breast Cancer Treatment

• Surgery (Lumpectomy, Mastectomy)

• Chemotherapy

• Radiation therapy

• Immunotherapy

• Targeted therapy (PARP inhibitors, ADCs)

TNBC Drug Class Analysis

• PD-1/PD-L1 Inhibitors

• PARP Inhibitors

• Antibody-Drug Conjugates (ADCs)

TNBC End-User Outlook (Revenue, USD Million, 2025 - 2034)

• Hospitals and Specialty Clinics

• Cancer Treatment Centers

• Others

TNBC Regional Outlook (Revenue, USD Million, 2025 - 2034)

• The U.S.

• Europe (Germany, France, Italy, Spain, the UK)

• Asia Pacific (Japan)

List of Key Players in the TNBC Market

• Merck

• Roche

• AstraZeneca

• Pfizer

• Gilead Sciences

• Daiichi Sankyo

• OBI Pharma

• Astellas Pharma

• BioNTech

• Galera Therapeutics, and others.

The TNBC market is experiencing steady growth driven by technological advancements in targeted therapy, increasing disease prevalence, and expanding pipeline of innovative treatments. The overall market is projected to grow significantly, driven by increasing biomarker testing, better patient selection, and continued advancements in ADCs, checkpoint inhibitors, PARP inhibitors, and novel immune-based approaches.

The comprehensive DelveInsight’s Triple Negative Breast Cancer Market Report provides pharmaceutical executives with the detailed market intelligence, competitive analysis, and strategic insights necessary to navigate this complex and rapidly evolving therapeutic landscape.

1234 1234